Screener
Prime Medicine PRME Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands) | Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value |
|---|---|---|---|---|
| Short-term investments in debt securities: | ||||
| U.S. Treasury and government securities | $36,074 | — | $(4) | $36,070 |
| Corporate debt securities | 11,555 | — | (5) | 11,550 |
| Total short-term investments in debt securities | $47,629 | — | $(9) | $47,620 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's unrealized gains on investments?
- Prime Medicine (PRME) reported unrealized gains on investments of $0 in Q2 2026.
- What does unrealized gains on investments mean?
- The total unrealized gains on investments, typically related to available-for-sale securities.
Ask your AI about Prime Medicine's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude